Amphstar Pharmaceuticals vs Emergent BioSolutions
Emergent BioSolutions reported revenue of $743 million in fiscal 2025, about the same as Amphstar Pharmaceuticals' $720 million in fiscal 2025. Amphstar Pharmaceuticals' revenue fell 1.6% in its latest year, and Emergent BioSolutions' fell 28.8%. Amphstar Pharmaceuticals had an operating margin of 19.5%, against 13.5% at Emergent BioSolutions. Free cash flow was $121 million at Amphstar Pharmaceuticals and $157 million at Emergent BioSolutions.
Side by side
| Amphstar Pharmaceuticals | Emergent BioSolutions | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $720M | $743M |
| Revenue growth | −1.6% | −28.8% |
| Revenue growth a year, last 5 years | 15.5% | −14.0% |
| Gross margin | 49.5% | 56.1% |
| Operating margin | 19.5% | 13.5% |
| Net margin | 13.6% | 7.1% |
| Free cash flow | $121M | $157M |
| Free cash flow margin | 16.8% | 21.1% |
| Return on capital | 9.9% | 6.4% |
| Net debt to EBITDA | 1.7x | 2.0x |
| Dividends and buybacks | $76M | $25M |
| Change in diluted share count | −7.4% | 7.0% |
| Last close | $28.11 | $5.15 |
| P/E at the last close | 12.8× | — |
| Insider trades, last 12 months | sold $2.4 million | sold $840,301 |
| Piotroski F-score | 6 of 9 | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Amphstar PharmaceuticalsEmergent BioSolutions
Operating margin
Percent of revenue
Amphstar PharmaceuticalsEmergent BioSolutions
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Amphstar PharmaceuticalsEmergent BioSolutions
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Amphstar Pharmaceuticals and Emergent BioSolutions pages.